肖志坚,郝玉书.骨髓增生异常综合征的治疗选择[J].中华内科杂志,2007,46(4):265-267.

肖志坚,郝玉书.规范我国骨髓增生异常综合征的实验室检查和诊断[J].中华血液学杂志,2008,29(1):1-2.

肖志坚.重视骨髓增生异常综合征铁过载的诊断和治疗[J].中华血液学杂志,2011,32(8):505-506.

肖志坚.进一步规范和提高我国骨髓增生异常综合征的诊治策略[J].中华血液学杂志,2012,33:505-506.

KOHLMANN A,GROSSMANN V,NADARAJA-H N,et al.Next-generation sequencing-feasibility and practicality in haematology[J].Br J Haematol,2013,160:736-753.

RAZA A,GALILI N.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes[J].Nat Rev Cancer,2012,12:849-859.

WANG J,AI X,GALE R P,et al.TET2,ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes[J].Leuk Res,2013,37:305-311.

CUI R,GALE R P,XU Z,et al.Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts[J].Leuk Res,2012,36:1428-1433.

SCHANZ J,TUCHLER H,SOLE F,et al.New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge[J].J Clin Oncol,2012,30:820-829.

GREENBERG P L,TUECHLER H,SCHANZ J,et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood,2012,120:2454-2465.

QU S,XU Z,ZHANG Y,et al.Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes:results of a single-center study[J].Leuk Lymphoma,2012,53:940-946.

GARCIA-MANERO G,JABBOUR E,BORTHAKUR G,et al.Randomized Open-Label Phase II Study of Decitabine in Patients With Low-or Intermediate-Risk Myelodysplastic Syndromes[J].J Clin Oncol,2013[Epub ahead of print].